Meet Know Labs – An Emerging Leader In Non-Invasive Medical Diagnostic Technology

SSupported by cloud service provider DigitalOcean – Try DigitalOcean now and receive a $200 when you create a new account!
Listen to this article

Below is our recent interview with Leonardo Trautwein, Chief Marketing Officer at Know Labs:

Q: Could you provide our readers with a brief introduction to your company?

A: Know Labs is an emerging leader in non-invasive medical diagnostic technology, developing what it believes will be the world’s first FDA-cleared, medical-grade, non-invasive glucose monitoring device. A portable on-demand monitoring device, KnowU, is nearing the final stages of development and testing prior to beginning the FDA application. In addition to the KnowU, Know Labs is developing the UBand, a wearable continuous glucose monitoring device. The company’s patented, proprietary Bio-RFID™ technology uses radiofrequency spectroscopy to detect and measure the presence of analytes, such as glucose molecules, in the bloodstream. The technology is form-factor agnostic, provides a pain-free experience, and does not require any sort of consumables. As a platform technology, it has the potential to be applied to more than 100 different analytes. Know Labs is a public company whose shares trade on the OTCQB market under the stock symbol KNWN.

Recommended: Infosec Provides Role-Guided Cybersecurity Education For The Entire Organization

Q: Any highlights on your recent announcement?

A: The company’s proprietary Artificial Intelligence (AI) Deep Learning Platform enables the Know Labs Bio- RFID technology to identify and measure blood glucose levels accurately and non-invasively. Know Labs announced the creation of a new subsidiary, AI Mind Inc., focused on working with this AI engine and on identifying opportunities to monetize it. The same AI engine that controls the Bio-RFID technology now has begun to generate millions in revenue, approximately $4.2M, which will be used to help fund the Company’s vision. In our opinion, AI will be intrinsic to all industries moving forward and now we understand how big the societal impact of AI will be.

Q: Can you give us more insights into your offering?

A: We are currently developing a wristband-style device as well as a palm-scanning device that will eliminate the need to pierce the skin to get glucose readings.

KnowU: designed to replace traditional fingerstick glucose meters. It is small enough to fit into your pocket and doesn’t require test strips. This is aimed at people with diabetes who aren’t interested in a wearable continuous glucose monitor (CGM) but want more of a traditional meter for on-the-go use without the painful and expensive finger sticks.

UBand: is a wearable device with built-in Bio-RFID sensor, designed to continuously monitor glucose levels. It won’t have a display screen, but instead, the readings will be sent directly to a smartphone app. This product is aimed at people with diabetes who are interested in a non-invasive CGM.

In vitro and in vivo tests using a Bio-RFID prototype have confirmed that Bio-RFID measures blood- glucose levels with medical-grade accuracy, as accurately as finger-sticks and the two best-known brands of minimally-invasive continuous glucose monitors, Dexcom G6 and Abbott Freestyle Libre. More details on these results can be found in this report.

Glucose monitoring is our priority, but Bio-RFID is a non-invasive diagnostic technology platform that can potentially identify and measure hundreds of analytes in your body. Building upon this technology platform, the Company plans to continue researching other analytes, which should provide useful and life-saving information to enhance the health and wellness of people around the world.

Recommended: RegScale Delivers Continuous Compliance Automation For Highly Regulated Public And Private Sector Entities

Q: What can we expect from your company in next 6 months? What are your plans?

A: Our team continues to be focused on bringing non-invasive diagnostic devices to market. We will soon kick-off a 200-participant internal clinical trial to refine our AI algorithms and further validate our technology’s accuracy. This will be another important step toward the FDA approval process, which we expect to commence in 2022. In parallel to this, we’ll continue to seize opportunities to create incremental value for our shareholders, including through our new subsidiary focused on our AI Deep Learning Platform.

In February of 2021, we announced our plans to uplist to a major national exchange, such as NASDAQ and NYSE. We will provide more updates on this as things progress.

Q: What is the best thing about your company that people might not know about?

A: We are transforming non-invasive medical diagnostics. We are committed to making a difference in the lives of millions of people around the world. Glucose is only the start of a prosperous journey.